Investment Summary |
|
|---|---|
| Date | 2017-01-01 |
| Target | Swixx Biopharma |
| Sector | Distribution |
| Investor(s) |
HBM Partners AG
Merieux Equity Partners |
| Deal Type | Growth Capital |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Private Equity Firm |
|---|---|
| Founded | 2001 |
| PE ASSETS | 3.0B USD |
| Size | Mega |
| Type | Sector Focused |
HBM Partners is a private investment firm focused on investing in entrepreneurial biopharma and other healthcare-related companies in Europe, North America, India and other Emerging Markets. HBM looks to invest $5 to $50 million per transaction and will consider private and public companies. HBM Partners was established in 2001 and is headquartered in Zug, Switzerland.
| DEAL STATS | # |
|---|---|
| Overall | 13 of 66 |
| Sector (Distribution) | 1 of 1 |
| Type (Growth Capital) | 2 of 7 |
| Country (Switzerland) | 3 of 4 |
| Year (2017) | 1 of 6 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2016-10-12 |
ObsEva
Geneva, Switzerland ObsEva is a biopharmaceutical company developing novel therapeutics in women's health for the treatment of symptoms associated with endometriosis and uterine fibroids. ObsEva was founded in 2012 and is headquartered in Geneva, Switzerland. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2017-01-06 |
Neurelis
San Diego, California, United States Neurelis is a specialty pharmaceutical company organized to license, develop, and commercialize product candidates for the treatment of central nervous system disorders with a focus on the treatment of acute breakthrough seizures (epilepsy) and acute anxiety episodes. Neurelis was founded in 2007 and is based in San Diego, California. |
Buy | - |
| Category | Growth Capital Firm |
|---|---|
| Founded | 2009 |
| PE ASSETS | 1.3B EUR |
| Size | Large |
| Type | Sector Focused |
Mérieux Développement SAS is a venture and growth capital investment firm associated with family holding company Institut Mérieux. The Firm focuses on the health and nutrition sectors and will consider opportunities throughout North America and Europe. Mérieux Développement SAS was established in 2009 and is headquartered in Lyon, France.
| DEAL STATS | # |
|---|---|
| Overall | 5 of 20 |
| Sector (Distribution) | 1 of 1 |
| Type (Growth Capital) | 2 of 6 |
| Country (Switzerland) | 1 of 1 |
| Year (2017) | 1 of 2 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2016-03-21 |
Seqens
Ecully, France Seqens is a global diversified chemicals Group that produces and distributes essential chemicals that are used in everyday products. Seqens offers a broad portfolio of active ingredients, pharmaceutical intermediates, and specialty ingredients, develops and industrializes the most demanding molecules, and relies on its ability to innovate, develop and implement the best available technologies. Seqens was founded in 2003 and is based in Ecully, France. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2017-06-09 |
SERB Pharmaceuticals
Luxembourg, Luxembourg SERB Pharmaceuticals is an independent niche specialty pharma company focused on niche branded prescription medicines. The company has a strong focus on therapeutic areas such as critical and emergency care, neurology, diagnostics and endocrinology. SERB Pharmaceuticals was founded in 1951 and is based in Luxembourg. |
Buy | - |
